StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
BIS.BK$2.06-1.90%
Fair $2.06+0.0%

BIS.BK

Bioscience Animal Health Public Company Limited

Consumer Defensive / Packaged FoodsThailand

$2.06

-0.04 (-1.90%)

Fairly Valued+0.0%Fair Value $2.06Fund rank 28/100 · Data gapFallback financials|
SA 46/C
F-Score: 5/9
Declining RevenueLow Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 19%

FCF escenarios

weak_data · normalized FCF $97.4M · quality 49.0/100

Data gap 28/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 19/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

46/100

C

Piotroski

5/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 2unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. Revenue has declined for 2 consecutive years ROE is 4.9%, below the 5% threshold
Thesis & Journal · BIS.BKLocal privado en este navegador · Bioscience Animal Health Public Company Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$647M

P/E

17.2x

↑

EV/EBITDA

7.8x

↓

ROE

4.9%

↓

Gross Margin

15.2%

↓

Debt/Equity

0.01

↓
52-Week Range$2
$2$3

TradingView lightweight chart

BIS.BK price, volumen y niveles de valoración

Último $2.060Periodo -76.9%
Fair value: $2.060

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+0.9%

FCF CAGR

—

FCF margin

12.1%

FCF / Net income

7.11x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $2.25B · net income $38.5M · FCF $273.6M

2022-FY → 2025-FY

Gross margin

15.2%+0.7% pts

Operating margin

2.5%-1.2% pts

Net margin

1.7%-0.8% pts

FCF margin

12.1%+14.4% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$2.25B$2.25B$2.32B$2.41B$2.19B
Net Income$38.5M$38.5M$65.0M$50.7M$55.9M
EBITDA$76.9M$76.9M$113.5M$84.7M$97.8M
EPS——0.210.160.20
Gross Margin15.2%15.2%14.9%13.8%14.4%
Operating Margin2.5%2.5%4.1%2.8%3.7%
Net Margin1.7%1.7%2.8%2.1%2.5%
Balance Sheet
Debt/Equity0.010.010.070.010.01
Current Ratio2.362.36———
Cash Flow
Free Cash Flow$273.6M$273.6M$97.4M$-31.0M$-50.3M
Returns
ROE4.9%4.9%8.1%6.5%7.3%
Valuation
P/E17.1717.1714.7829.3241.12
EV/EBITDA7.817.817.8317.2723.34
P/B0.830.831.201.903.02
Growth & Yield
Revenue Growth-3.0%-3.0%-3.7%9.9%—
EPS Growth——28.6%-18.3%—
Dividend Yield4.0%4.0%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -19.2%

Total return

-19.2%

Start / end P/E

n/dx → n/dx

EPS bridge

0.21 → n/d

Residual

-23.1%

EPS growthn/d
Multiple reratingn/d
Dividend+4.0%
Residual / FX / buybacks / cross-term-23.1%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.